Glenmark Pharmaceuticals Ltd - GLENMARK PHARMA. Share Price

Sector: Pharmaceuticals | ISIN: INE935A01035
₹ 1,034.50 (-0.47%) icon23 Apr, 2024, 12:00:00 AM
Open
₹ 1,039.35
Prev. Close
₹ 1,039.35
Turnover(lac)
₹ 0.13
Day's High
₹ 1,044.25
Day's Low
₹ 1,017.50
52 Wk High
₹ 1,070.00
52 Wk Low
₹ 507.40
Book Value
₹ 653.15
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 29,192.36
P/E
27.73
EPS
37.29
Div. Yield
0.24

Glenmark Pharmaceuticals Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/23/2024 12:00:00 AM

    ₹ 1034.5 -4.85 -0.47
  • Open
  • ₹ 1,039.35
  • Prev. Close
  • ₹ 1,039.35
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 1,044.25
  • Day's Low
  • ₹ 1,017.5
  • 52 Week's High
  • ₹ 1,070
  • 52 Week's Low
  • ₹ 507.4
  • Book Value
  • ₹ 653.15
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 29,192.36
  • P/E
  • 27.73
  • EPS
  • 37.29
  • Divi. Yield
  • 0.24

Glenmark Pharmaceuticals Ltd Corporate Actions

30 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

30 Jan , 2024

12:00 AM

31 Oct , 2023

12:00 AM

31 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

05 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Aug , 2023

12:00 AM

AGM

Announcement date: 25 Aug , 2023

View Details

21 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 May , 2023

12:00 AM

Dividend

Dividend amount: 2.5
Announcement date: 19 May , 2023

View Details

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

03 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Aug , 2023

12:00 AM

BookCloser

View Details

No Record Found


Glenmark Pharmaceuticals Ltd News and Update

Image not found

With more than 150 scientists, the new organization will make use of its three international innovation hubs.

Image not found

Glenmark Makes Strategic Japan Play in Pharma Deal

This project is predicted to have a commercial value of approximately $5 million.

  • 19 Jan, 2024 |
  • 10:52 AM
Image not found

Dr Reddy's, Glenmark, and Zydus Recall Products in the US Over Manufacturing Issues

Recalls by Dr Reddy's, Glenmark, and Zydus in the US are designated as Class II by the USFDA.

  • 22 Nov, 2023 |
  • 3:44 PM
Image not found

Glenmark launches triple FDC of Teneligliptin with Pioglitazone, Metformin in India

According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, of which 77% would have uncontrolled diabetes.

  • 18 Oct, 2023 |
  • 10:51 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Glenmark Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT
24 April , 2024 | 08:56 AM

PROMOTER - TOTAL46.64%

Indian: 46.64%

Foreign: 0%

NON-PROMOTER - TOTAL 53.36%

Institutions: 34.78%

Non-Institutions: 18.58%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Glenmark Pharmaceuticals Ltd FINANCIALS

Glenmark Pharmaceuticals Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Glenmark Pharmaceuticals Ltd

  • Glenn Saldanha
  • Chairman / Executive Director
  • Cheryl Pinto
  • Executive Director (Corporate)
  • V S Mani
  • Executive Director & Group CFO
  • B E Saldanha
  • Non Executive Director
  • Rajesh Desai.
  • Independent Non Exe. Director
  • Devendra Raj Mehta
  • Independent Non Exe. Director
  • Bernard Munos
  • Independent Non Exe. Director
  • Brian W Tempest
  • Independent Non Exe. Director
  • Sridhar Gorthi
  • Independent Non Exe. Director
  • Sona Saira Ramasastry
  • Independent Non Exe. Director
  • Dipankar Bhattacharjee
  • Independent Non Exe. Director
  • V R Iyer
  • Independent Non Exe. Director

Summary

Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India.In the year 1979, the company entered dermatology market with the launch of Candid Cream. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril.In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded... Read More


Reports by Glenmark Pharmaceuticals Ltd


Reports by Glenmark Pharmaceuticals Ltd

Company FAQ

No Record Found